Written and published by Biogerontology Research Foundation staff in collaboration with Novartis Pharma AG, Department of Developmental and Molecular Pathways, Novartis Institute for Biomedical Research.
Zhavoronkov A(1), Bhullar B(2).
(1) The Biogerontology Research Foundation , Oxford, UK ; Insilico Medicine Inc , Baltimore, MD, USA.
(2) Novartis Pharma AG, Department of Developmental and Molecular Pathways, Novartis Institute for Biomedical Research , Basel, Switzerland.
Abstract: Aging is a complex continuous multifactorial process leading to loss of function and crystalizing into the many age-related diseases. Here, we explore the arguments for classifying aging as a disease in the context of the upcoming World Health Organization's 11th International Statistical Classification of Diseases and Related Health Problems (ICD-11), expected to be finalized in 2018. We hypothesize that classifying aging as a disease with a "non-garbage" set of codes will result in new approaches and business models for addressing aging as a treatable condition, which will lead to both economic and healthcare benefits for all stakeholders. Actionable classification of aging as a disease may lead to more efficient allocation of resources by enabling funding bodies and other stakeholders to use quality-adjusted life years (QALYs) and healthy-years equivalent (HYE) as metrics when evaluating both research and clinical programs. We propose forming a Task Force to interface the WHO in order to develop a multidisciplinary framework for classifying aging as a disease with multiple disease codes facilitating for therapeutic interventions and preventative strategies.